- A rare fungus mimicked recurring cancer in a lymphoma survivor's lungs
- Helps doctors and patients avoid dangerous misdiagnosis after cancer treatment
- Single case report — more research needed before changing standard practice
A patient was told their lymphoma was back. It turned out to be a drug-resistant fungus hiding in plain sight.
When the scan tells the wrong story
Imagine surviving cancer. Then a year later, a scan shows something growing in your lungs again.
Your doctor tells you the lymphoma is back. You start preparing for the worst. But what if the shadow on that scan was not cancer at all?
That is exactly what happened to one patient described in a new case report from Frontiers in Medicine. The real culprit was a stubborn fungus called Candida tropicalis. And the case is teaching doctors an important lesson about second opinions.
A quiet but serious threat
Invasive pulmonary fungal disease, or IPFD, is a lung infection caused by fungi growing inside the lung tissue. It is rare in healthy people. But it can be deadly in people with weak immune systems.
The tricky part? It often looks like other things on imaging. It can mimic pneumonia, tuberculosis, or even cancer.
People who have had cancer treatment, organ transplants, or long courses of steroids are at higher risk. Their immune system is not strong enough to keep fungi in check. And because IPFD is uncommon, many doctors do not think to test for it first.
What everyone assumed
For decades, when a cancer survivor shows a new lung mass, the first thought is recurrence. That assumption usually makes sense. Cancer can come back, and catching it early matters.
But here is the twist.
Sometimes the immune system, weakened by past chemo or other illness, lets opportunistic infections move in. These infections can grow in ways that look exactly like a tumor on a CT scan. Without a biopsy or special lab tests, the difference is nearly impossible to spot.
How a fungus fools the lungs
Think of your immune system as a security team patrolling your body. In a healthy person, that team spots fungal spores and removes them before they cause trouble.
But when the security team is short-staffed — say, after cancer treatment — those spores can settle in. They grow into colonies inside lung tissue. Over time, the colonies form solid masses that show up on imaging as suspicious "growths."
To the eye and to a scanner, these masses can look just like a tumor. Only deeper testing reveals what is really inside.
Inside the case report
In this report, the patient had a history of lymphoma. A different hospital looked at their lung scan and diagnosed recurrent cancer.
When the patient came to a new medical team, doctors took a closer look. They ran three tests: a tissue biopsy (histopathology), a sputum culture, and next-generation sequencing of fluid washed from the lungs (called bronchoalveolar lavage). All three pointed to the same answer — Candida tropicalis, not cancer.
The treatment twist
Doctors first tried fluconazole, a common antifungal medication. The patient did not improve.
That was a red flag. The fungus was resistant to the standard drug. So the team switched to caspofungin, a stronger antifungal from a different class. This time, the patient got substantially better.
This case is a reminder that not every lung mass in a cancer survivor is cancer coming back.
The deeper mystery
But there's a catch. Why did this patient suddenly become vulnerable to a serious fungal infection in the first place?
The team kept digging. They eventually found a hidden skin cancer that was likely suppressing the patient's immune system. That underlying problem had been quietly opening the door to the fungus all along.
Why this case matters
Doctors specializing in infectious disease and oncology have long warned that mimics of cancer recurrence exist. This case adds to that growing body of evidence.
It also highlights something important about modern medicine. New tools like next-generation sequencing can identify infections that older tests miss. And drug-resistant fungi are becoming more common, which means treatment plans may need to change quickly when the first option fails.
If you or a loved one is a cancer survivor and a new lung problem appears, ask questions. A second opinion or additional testing — like a biopsy or fluid analysis — can help confirm what is really going on.
This does not mean every lung shadow is a fungus. Cancer recurrence is still the most likely cause in many cases. But knowing that other explanations exist can guide better conversations with your care team.
Honest limits of one case
This is a single case report. It describes one patient's experience, not a clinical trial with hundreds of people.
That means the findings cannot prove how often this kind of misdiagnosis happens. It also cannot tell us the best testing order for every patient. Larger studies would be needed to set firm guidelines.
What comes next
Researchers are watching drug-resistant Candida strains closely. As resistance spreads, doctors may need new testing routines and updated treatment plans for high-risk patients.
For now, cases like this one push the medical community to think more broadly. They remind doctors to consider infections, not just cancer, when survivors face new symptoms. And they remind all of us that getting the right diagnosis sometimes takes more than one look.